Orlistat-d3
(Synonyms: (–)-Tetrahydrolipstatin-d3) 目录号 : GC49236An internal standard for the quantification of orlistat
Cas No.:1356930-46-5
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Orlistat-d3 is intended for use as an internal standard for the quantification of orlistat by GC- or LC-MS. Orlistat is a digestive lipase inhibitor.1,2,3 It inhibits diacylglycerol lipase α (DAGLα), DAGLβ, α/β-hydrolase domain-containing protein 12 (ABHD12), ABHD16A, and platelet-activating factor acetylhydrolase (PAF-AH; IC50s = 0.06, 0.1, 0.08, 0.03, and 0.05 µM, respectively), as well as pancreatic lipase and hormone-sensitive lipase (IC50s = 0.65 and 2.1 µg/ml, respectively) but does not inhibit fatty acid amide hydrolase (FAAH) or KIAA1363 (IC50s = >100 µM for both). Orlistat decreases ionomycin-induced production of the endocannabinoid 2-arachidonoyl glycerol (2-AG) in N18TG2 murine neuroblastoma cells when used at a concentration of 1 µM.4 It also inhibits fatty acid synthase (FASN; Kiapp = ~0.1 µM for the human enzyme) and the proliferation of PC3 prostate cancer cells in a concentration-dependent manner.5 Orlistat (10 mg/kg) decreases serum cholesterol levels and total body weight in a mouse model of obesity induced by a high-fat diet.6 Formulations containing orlistat have been used in the treatment of adult obesity.
1.Bisogno, T., Howell, F., Williams, G., et al.Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brainJ. Cell Biol.163(3)463-468(2003) 2.Hoover, H.S., Blankman, J.L., Niessen, S., et al.Selectivity of inhibitors of endocannabinoid biosynthesis evaluated by activity-based protein profilingBioorg. Med. Chem. Lett.18(22)5838-5841(2008) 3.Bustanji, Y., Issa, A., Mohammad, M., et al.Inhibition of hormone sensitive lipase and pancreatic lipase by Rosmarinus officinalis extract and selected phenolic constituentsJ. Med. Plant Res.4(21)2235-2242(2010) 4.Bisogno, T., Cascio, M.G., Saha, B., et al.Development of the first potent and specific inhibitors of endocannabinoid biosynthesisBiochim. Biophys. Acta1761(2)205-212(2006) 5.Kridel, S.J., Axelrod, F., Rozenkrantz, N., et al.Orlistat is a novel inhibitor of fatty acid synthase with antitumor activityCancer Res.64(6)2070-2075(2004) 6.Ji, W., Zhao, M., Wang, M., et al.Effects of canagliflozin on weight loss in high-fat diet-induced obese micePLoS One12(6)e0179960(2017)
Cas No. | 1356930-46-5 | SDF | |
别名 | (–)-Tetrahydrolipstatin-d3 | ||
Canonical SMILES | [2H]C([2H])([2H])C(C)C[C@H](NC=O)C(O[C@@H](CCCCCCCCCCC)C[C@@H]1OC([C@H]1CCCCCC)=O)=O | ||
分子式 | C29H50D3NO5 | 分子量 | 498.8 |
溶解度 | Chloroform: slightly soluble,Methanol: slightly soluble | 储存条件 | -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.0048 mL | 10.0241 mL | 20.0481 mL |
5 mM | 0.401 mL | 2.0048 mL | 4.0096 mL |
10 mM | 0.2005 mL | 1.0024 mL | 2.0048 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。